RSV Prevention Drug Missed by Most Infants, Study Reveals

Understanding the Challenges of RSV Prevention

New research from the Children’s Hospital of Philadelphia highlights the difficulties in getting families to accept a groundbreaking drug that offers protection against RSV, a common cold-like virus that can lead to severe illness and hospitalization in infants. The drug, Beyfortus, represents a significant advancement as it is the first preventive medication specifically designed for otherwise healthy infants against RSV.

Many medical professionals welcomed the FDA's approval of Beyfortus in 2023, seeing it as an opportunity to combat the highly contagious virus. This was especially relevant after the previous winter, when a "tripledemic" of respiratory illnesses overwhelmed children’s hospitals. However, the initial rollout of the drug faced challenges, with only 35% of eligible children receiving it in the first season following its launch. This data came from a study analyzing information from 32 practices within the CHOP Primary Care Network across Pennsylvania and New Jersey.

The research revealed that the lowest uptake occurred among children with public insurance, Black children, and those living in socioeconomically disadvantaged areas. The study, published in Pediatrics, included a sample size of 7,208 patients. Ericka Hayes, a senior medical director at CHOP who was not involved in the study, emphasized the importance of ensuring all young infants receive this treatment. She noted that while progress has been made, the numbers are still not where they need to be.

What Is RSV and Why Is It Dangerous?

RSV, or respiratory syncytial virus, typically causes mild symptoms such as a runny nose and cough. However, it can become dangerous, particularly for infants. Jeffrey Gerber, a pediatric infectious disease doctor at CHOP and senior author of the study, explained that the small airways of infants make them vulnerable to severe complications. In children under 12 months, RSV can quickly escalate into serious respiratory illness and pneumonia, often requiring hospitalization.

There is currently no specific treatment for RSV. Doctors manage symptoms by providing oxygen, administering IV fluids, and in some cases using mechanical ventilators. According to the Centers for Disease Control and Prevention, hundreds of children die from RSV each year in the U.S., with tens of thousands hospitalized due to severe illness.

Beyfortus has shown to reduce the likelihood of hospitalization by 80%. While it is not technically a vaccine, it is a monoclonal antibody—a type of protein that binds to a specific target. Think of antibodies as police officers patrolling the body for a specific threat. Once identified, the antibody "handcuffs" the threat and marks it for destruction. Beyfortus prevents the RSV virus from invading cells and causing disease.

How Does Beyfortus Work?

The treatment is administered as a single injection to infants under 8 months of age. It is intended to provide protection during the RSV season, which typically spans from fall to winter. After five to six months, the antibodies begin to break down, and the protective effect of the drug diminishes. Gerber described this as a way to "buy time" and get children through the season. By the next year, the child would be older and better equipped to handle RSV.

When Should Your Child Receive the Injection?

The CDC recommends that otherwise healthy infants under eight months of age receive Beyfortus between October and March. If a baby is born during this period, they should receive the injection at birth or within their first week of life. For those born outside this window, the injection can be given during any doctor visit. The optimal timing is shortly before the seasonal wave of RSV illness begins, typically between October and November.

Most families will not have to pay for the injection if they have insurance. Even for those without insurance or with limited coverage, the drug is available at no cost for eligible children through the federal government’s Vaccines for Children program. Another option is for pregnant individuals to receive the maternal RSV vaccine, Abrysvo, between 32 and 36 weeks of pregnancy during September through January.

Disparities in Uptake and the Path Forward

Gerber, the senior author of the study, did not find it surprising that only a third of children received the drug initially. After all, it was a new medication, and it was only its first season on the market. However, in the second season, uptake doubled to two-thirds of eligible children, according to more recent, unpublished data from the team at CHOP.

Despite this progress, racial and socioeconomic disparities in who received the drug remain significant. Hayes, the medical director of infection prevention and control at CHOP, pointed out that these disparities may reflect possible misinformation and hesitancy around new therapies. She encourages families to consult their primary care provider to make informed decisions.

Hayes shared a personal account of caring for a "perfectly healthy" 4-month-old child who rapidly became critically ill and required intensive care. "We always wished that we had some sort of treatment to help prevent this," she said. Her experience underscores the importance of leveraging available treatments like Beyfortus to protect infants from the dangers of RSV.